At the current time, pancreatic cancer remains a difficult and typically fa
tal disease. A number of case reports and case-control epidemiologic studie
s have suggested that familial aggregation plays a role in as many as 10% o
f all pancreatic cancers. During the last several years, genetic alteration
s responsible for syndromes linked with pancreatic cancer have been identif
ied. These genes include BRCA2, p16, PRSS1, STK11, and various mismatch rep
air genes. Unfortunately, most kindreds with a familiar aggregation cannot
be explained by one of these known genetic syndromes. Recent data from the
National Familial Pancreas Tumor Registry at Johns Hopkins have estimated t
he prospective risk of pancreatic cancer among first-degree relatives of pa
ncreatic cancer patients. The risk was estimated by comparing observed new
cases of pancreatic cancer to expected numbers. In families where three fir
st-degree relatives had been diagnosed with pancreatic cancer, the risk of
another individual developing pancreatic cancer rose to a 57-fold increase
over the basal risk. This article reviews the data concerning familial panc
reatic cancer. Additionally, this article reviews the data concerning the h
istological precursors of invasive ductal adenocarcinoma of the pancreas: p
ancreatic intraepithelial neoplasias. Further, the current Johns Hopkins me
thodology used to screen for early pancreatic neoplasia in familial pancrea
tic cancer patients and in patients with familial Peutz-Jeghers syndrome is
discussed. In summary, the notable advances in the field of molecular gene
tics have allowed for a better definition of the genetics of pancreatic can
cer. With this knowledge has evolved a better understanding of several high
-risk clinical syndromes associated with pancreatic cancer, familial pancre
atic cancer, and the evolution of strategies to screen high-risk families f
or early pancreatic neoplasia. Copyright (C) 2001 S. Karger AG, Basel.